Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight

Endometrial Cancer Pipeline Summary
By 2025, the Endometrial Cancer pipeline features over 45 active candidates, emphasizing PD-1/PD-L1 inhibitors, PI3K/AKT/mTOR inhibitors, hormone receptor-targeted agents, and combinations for MSI-H and p53-mutated tumors. Key players such as Eisai, GSK, Seagen, Gilead Sciences, and Regeneron are advancing late-stage programs.

DelveInsight's "Endometrial Cancer Pipeline Insight, 2025" delivers an in-depth review of clinical progress, biomarker-driven approaches, and the expanding role of immunotherapy across treatment lines. The report also highlights recent FDA designations and pivotal trials poised to reshape care standards. With increasing focus on biomarker-based stratification and earlier-line immunotherapy, the endometrial cancer pipeline is rapidly advancing, offering new opportunities for more personalized and durable patient outcomes.

Endometrial cancer, the most prevalent gynecologic cancer in developed nations, is experiencing significant changes in treatment, particularly for advanced and recurrent cases where conventional options provide limited survival benefit. The growing adoption of molecularly guided therapies and immune checkpoint inhibitors is transforming the therapeutic landscape.

Interested in learning more about the current treatment landscape and the key drivers shaping the endometrial cancer pipeline? Click here: https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Endometrial Cancer Pipeline Report
• DelveInsight's endometrial cancer pipeline analysis depicts a strong space with 45+ active players working to develop 50+ pipeline drugs for endometrial cancer treatment.
• In March 2025, updated Phase III data from the ENGOT‐EN6‐NSGO/GOG‐3031/RUBY trial showed that dostarlimab‐gxly (Jemperli) combined with carboplatin and paclitaxel extended median duration of response (DOR) by 4.4 months versus chemotherapy alone in advanced or recurrent endometrial cancer.
• In February 2025, the OncoSignature multiplex immunofluorescence assay received FDA breakthrough device designation for identifying endometrial cancer patients who may benefit from ACR-368 (prexasertib) treatment.
• In February 2025, Acrivon Therapeutics announced that the FDA granted Breakthrough Device designation for its ACR-368 OncoSignature assay. This multiplex immunofluorescence assay is designed to identify endometrial cancer patients who may benefit from ACR-368 treatment.
• The leading endometrial cancer companies include Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others are evaluating their lead assets to improve the endometrial cancer treatment landscape.
• Key endometrial cancer pipeline therapies in various stages of development include LENVIMA, Mirvetuximab soravtansine, XMT 1660, VLS-1488, ZW25, XB002, Trastuzumab deruxtecan, TQB2450, TPST-1495, TOS-358, TORL-1-23, TNG260, TH1902, SYD985, SKB264, SGN-STNV, SGNB 7H4V, Selinexor, RGX-104, Dordaviprone, and others.

Request a sample and discover the recent breakthroughs happening in the endometrial cancer pipeline landscape at https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Endometrial Cancer Overview
Endometrial cancer is the most common gynecologic malignancy in developed countries, primarily affecting the lining of the uterus (endometrium). It typically arises in postmenopausal women, although younger women can also be affected. The majority of cases are diagnosed at an early stage due to abnormal uterine bleeding, which often prompts timely medical evaluation.

There are two main types: Type I, which is estrogen-dependent and often linked to obesity, diabetes, and unopposed estrogen exposure, and Type II, which is more aggressive and estrogen-independent. While early-stage endometrial cancer has a favorable prognosis with surgery alone, advanced or recurrent disease often requires a multimodal approach including radiation, chemotherapy, and emerging targeted therapies. Advances in molecular profiling and immunotherapy are helping to shape more personalized treatment strategies in this evolving therapeutic landscape.

Find out more about endometrial cancer medication at https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Endometrial Cancer Treatment Analysis: Drug Profile
Selinexor - Karyopharm Therapeutics
Selinexor (XPOVIO) is a first-in-class, oral selective inhibitor of nuclear export (SINE) that blocks exportin 1 (XPO1). By inhibiting XPO1, it enhances nuclear retention of tumor suppressor proteins, triggering apoptosis in cancer cells. The drug is under investigation as a maintenance therapy for advanced or recurrent endometrial cancer, particularly in TP53 wild-type patients. Results from the Phase III SIENDO trial showed meaningful improvements in progression-free survival (PFS) in this subgroup, and selinexor is currently in late-stage Phase III development.

Abemaciclib - Eli Lilly and Company
Abemaciclib, a CDK4/6 inhibitor by Eli Lilly, has demonstrated promising activity when combined with hormonal therapy in recurrent estrogen receptor (ER)-positive endometrioid endometrial cancer (EEC). In a Phase II trial, the combination achieved a 67% clinical benefit rate, with partial and complete responses and a median PFS of 6.1 months. Another study pairing abemaciclib with letrozole reported a 30% objective response rate and a median PFS of 9.1 months, further enhanced with the addition of metformin due to multi-pathway targeting. These outcomes position abemaciclib-based combinations as a strong therapeutic option in ER-positive EEC, with trials ongoing.

NP137 - NETRIS Pharma
NP137, a humanized IgG1 monoclonal antibody developed by NETRIS Pharma, targets netrin-1, a protein overexpressed in tumors and associated with resistance and disease progression. By inhibiting netrin-1, NP137 restores apoptosis and counters epithelial-to-mesenchymal transition (EMT), mechanisms contributing to therapeutic resistance. Preclinical and early clinical findings show anti-tumor potential both as monotherapy and in combination with chemotherapy or immunotherapy. With a favorable safety profile, NP137 is advancing through Phase II clinical development for endometrial cancer.

Learn more about the novel and emerging endometrial cancer pipeline therapies at https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Endometrial Cancer Therapeutics Assessment
Endometrial Cancer By Product Type
• Mono
• Combination
• Mono/Combination.

Endometrial Cancer By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Endometrial Cancer By Route of Administration
• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Endometrial Cancer By Molecule Type
• Small molecules
• Natural metabolites
• Monoclonal antibodies

Scope of the Endometrial Cancer Pipeline Report
• Coverage: Global
• Key Endometrial Cancer Companies: Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
• Key Endometrial Cancer Pipeline Therapies: LENVIMA, Mirvetuximab soravtansine, XMT 1660, VLS-1488, ZW25, XB002, Trastuzumab deruxtecan, TQB2450, TPST-1495, TOS-358, TORL-1-23, TNG260, TH1902, SYD985, SKB264, SGN-STNV, SGNB 7H4V, Selinexor, RGX-104, Dordaviprone, and others.

Dive deep into rich insights for drugs used for endometrial cancer treatment, visit: https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.